2. Academic Validation
  3. Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway

Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway

  • Bioorg Med Chem Lett. 2008 Feb 1;18(3):1027-30. doi: 10.1016/j.bmcl.2007.12.018.
Frédéric Stauffer 1,  Sauveur-Michel Maira,  Pascal Furet,  Carlos García-Echeverría
Affiliations

Affiliation

  • 1 Novartis Institute for BioMedical Research, Oncology Drug Discovery, Klybeckstrasse 141, Postfach, CH-4002 Basel, Switzerland. frederic.stauffer@novartis.com
PMID: 18248814 DOI: 10.1016/j.bmcl.2007.12.018
Abstract

Imidazo[4,5-c]quinoline derivatives have been discovered and developed as potent and effective modulators of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) pathway to lead to clinical development candidates. The SAR data of representative examples of this compound class and their biological profiling in cellular and in vivo settings are presented and discussed.

Figures